| Androgen deprivation therapy for prostate cancer N Sharifi, JL Gulley, WL Dahut Jama 294 (2), 238-244, 2005 | 1319 | 2005 |
| Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer PW Kantoff, TJ Schuetz, BA Blumenstein, LM Glode, DL Bilhartz, ... Journal of Clinical Oncology 28 (7), 1099-1105, 2010 | 1208 | 2010 |
| Avelumab, an anti–programmed death-ligand 1 antibody, in patients with refractory metastatic urothelial carcinoma: results from a multicenter, phase ib study AB Apolo, JR Infante, A Balmanoukian, MR Patel, D Wang, K Kelly, ... Journal of Clinical Oncology 35 (19), 2117-2124, 2017 | 657 | 2017 |
| Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial MR Patel, J Ellerton, JR Infante, M Agrawal, M Gordon, R Aljumaily, ... The Lancet Oncology 19 (1), 51-64, 2018 | 633 | 2018 |
| Antibody-dependent cellular cytotoxicity activity of a novel anti–PD-L1 antibody avelumab (MSB0010718C) on human tumor cells B Boyerinas, C Jochems, M Fantini, CR Heery, JL Gulley, KY Tsang, ... Cancer immunology research 3 (10), 1148-1157, 2015 | 601* | 2015 |
| Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer WL Dahut, JL Gulley, PM Arlen, Y Liu, KM Fedenko, SM Steinberg, ... Journal of clinical oncology 22 (13), 2532-2539, 2004 | 453 | 2004 |
| Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer JL Gulley, PM Arlen, A Bastian, S Morin, J Marte, P Beetham, KY Tsang, ... Clinical Cancer Research 11 (9), 3353-3362, 2005 | 432 | 2005 |
| Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial ML Disis, MH Taylor, K Kelly, JT Beck, M Gordon, KM Moore, MR Patel, ... JAMA oncology 5 (3), 393-401, 2019 | 414 | 2019 |
| Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFβ, in advanced solid tumors J Strauss, CR Heery, J Schlom, RA Madan, L Cao, Z Kang, E Lamping, ... Clinical Cancer Research 24 (6), 1287-1295, 2018 | 384 | 2018 |
| Current landscape of immunotherapy in breast cancer: a review S Adams, ME Gatti-Mays, K Kalinsky, LA Korde, E Sharon, ... JAMA oncology 5 (8), 1205-1214, 2019 | 373 | 2019 |
| Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial RA Madan, M Mohebtash, PM Arlen, M Vergati, M Rauckhorst, ... The lancet oncology 13 (5), 501-508, 2012 | 368 | 2012 |
| A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. PM Arlen, JL Gulley, C Parker, L Skarupa, M Pazdur, D Panicali, ... Clinical cancer research: an official journal of the American Association …, 2006 | 361 | 2006 |
| Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer JL Gulley, PM Arlen, RA Madan, KY Tsang, MP Pazdur, L Skarupa, ... Cancer Immunology, Immunotherapy 59, 663-674, 2010 | 360 | 2010 |
| Phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM alone and sequentially with vaccinia-CEA (6D)-TRICOM, with and without granulocyte-macrophage colony … JL Marshall, JL Gulley, PM Arlen, PK Beetham, KY Tsang, R Slack, ... Journal of Clinical Oncology 23 (4), 720-731, 2005 | 356 | 2005 |
| Reviews of evidence regarding interventions to reduce tobacco use and exposure to environmental tobacco smoke DP Hopkins, PA Briss, CJ Ricard, CG Husten, VG Carande-Kulis, ... American journal of preventive medicine 20 (2), 16-66, 2001 | 335 | 2001 |
| Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label … JL Gulley, A Rajan, DR Spigel, N Iannotti, J Chandler, DJL Wong, J Leach, ... The Lancet Oncology 18 (5), 599-610, 2017 | 318 | 2017 |
| Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial CR Heery, G O'Sullivan-Coyne, RA Madan, L Cordes, A Rajan, ... The Lancet Oncology 18 (5), 587-598, 2017 | 317 | 2017 |
| The role of lineage plasticity in prostate cancer therapy resistance H Beltran, A Hruszkewycz, HI Scher, J Hildesheim, J Isaacs, EY Yu, ... Clinical cancer research 25 (23), 6916-6924, 2019 | 315 | 2019 |
| Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy WD Stein, JL Gulley, J Schlom, RA Madan, W Dahut, WD Figg, Y Ning, ... Clinical Cancer Research 17 (4), 907-917, 2011 | 275 | 2011 |
| Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease MM Boyiadzis, JM Kirkwood, JL Marshall, CC Pritchard, NS Azad, ... Journal for immunotherapy of cancer 6, 1-7, 2018 | 272 | 2018 |
Ravi A MadanNational Cancer InstituteVerified email at mail.nih.gov
